MedTrace Logo

Fecal Microbiota Transplantation to RESCUE Patients With Unresectable Hcc Progressors to First Line Therapy With AtezolizUmaB and Bevacizumab

NCT07276100 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2025-12-10

No results posted yet for this study

Summary

The purpose of this study is to evaluate whether fecal microbiota transplantation (FMT), when administered in combination with atezolizumab and bevacizumab, can improve treatment response in participants with hepatocellular carcinoma (HCC) whose disease has progressed during prior atezolizumab-bevacizumab therapy. The study will also assess the safety and feasibility of this treatment strategy.

Primary Objective:

To determine whether FMT can restore or enhance response to atezolizumab and bevacizumab following disease progression.

Participants will:

Receive a fecal microbiota transplantation (FMT).

Resume treatment with atezolizumab and bevacizumab, administered every 3 weeks.

Conditions

  • Hepato Cellular Carcinoma (HCC)

Interventions

OTHER

Fecal microbiota transplantation (FMT)

Fecal microbiota transplantation (FMT)

DRUG

Atezolizumab & Bevacizumab

Atezolizumab \& Bevacizumab

Sponsors & Collaborators

  • IRCCS Azienda Ospedaliero-Universitaria di Bologna

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-01-01
Primary Completion
2027-01-01
Completion
2029-01-01

Countries

  • Italy

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07276100 on ClinicalTrials.gov